Back to News
Market Impact: 0.2
Evogene Ltd. Announces Acute Graft-Versus-Host Disease (aGVHD) as Target Indication for Drug Discovery Program on October 28, 2026
Source: Nasdaq
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
On October 28, 2026, Evogene Ltd. selected acute graft-versus-host disease (aGVHD) as the target indication for an internal AI-driven drug discovery program. The program aims to develop a novel, potential first-in-class small-molecule therapeutic; the article provides no development milestones, financial figures, or clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
EVGN0.35
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Budget 2026 speech
- Microsoft's Big Bets on AI Start to Pay Off
- Asian shares fall as Alphabet earnings miss drags Wall St futures lower
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off